Position in ANAB
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$216,293
-$5,611,827 QoQ
Shares Held
5,850
-96.8% QoQ
Ownership
0.020%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2021
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ANAB Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Jump Financial, LLC holds $441,487,523 across 168 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IONS |
Ionis Pharmaceuticals Inc
|
306,330 | $24,288,904 | |
| 2 | VKTX |
Viking Therapeutics, Inc.
|
579,882 | $22,621,196 | |
| 3 | XENE |
Xenon Pharmaceuticals Inc.
|
260,730 | $15,737,662 | |
| 4 | CRSP |
CRISPR Therapeutics AG
|
277,952 | $15,159,500 | |
| 5 | BMRN |
Biomarin Pharmaceutical Inc
|
245,390 | $14,041,214 | |
| 6 | SRPT |
Sarepta Therapeutics, Inc.
|
679,445 | $12,209,626 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
|
16,242 | $10,127,536 | |
| 8 | RARE |
Ultragenyx Pharmaceutical Inc.
|
286,952 | $9,581,327 |
All Filings in ANAB
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $216,293 | 3,900 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $5,828,120 | 120,217 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $2,513,192 | 82,077 | Shares | Defined | 2025-11-13 | |
| 2024-09-30 | $1,307,569 | 39,032 | Shares | Defined | 2024-11-14 | |
| 2024-06-30 | $894,643 | 35,700 | Shares | Defined | 2024-11-14 | |
| 2023-06-30 | $595,147 | 29,260 | Shares | Sole | 2024-10-21 | |
| 2022-12-31 | $580,442 | 18,730 | Shares | Sole | 2023-02-14 | |
| 2022-09-30 | $343,084 | 13,449 | Shares | Sole | 2022-11-07 | |
| 2022-06-30 | $313,126 | 15,425 | Shares | Sole | 2022-08-09 | |
| 2021-09-30 | $322,728 | 11,900 | Shares | Sole | 2021-11-12 | |
| No filing history on record for this holder in this stock. | ||||||